367 related articles for article (PubMed ID: 27898687)
1. Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.
Simões EA; Anderson EJ; Wu X; Ambrose CS
PLoS One; 2016; 11(11):e0166226. PubMed ID: 27898687
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
6. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
7. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
Wang X; Li Y; Shi T; Bont LJ; Chu HY; Zar HJ; Wahi-Singh B; Ma Y; Cong B; Sharland E; Riley RD; Deng J; Figueras-Aloy J; Heikkinen T; Jones MH; Liese JG; Markić J; Mejias A; Nunes MC; Resch B; Satav A; Yeo KT; Simões EAF; Nair H; ;
Lancet; 2024 Mar; 403(10433):1241-1253. PubMed ID: 38367641
[TBL] [Abstract][Full Text] [Related]
8. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
[TBL] [Abstract][Full Text] [Related]
9. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
[No Abstract] [Full Text] [Related]
10. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
13. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons.
Carbonell-Estrany X; Quero J;
Pediatr Infect Dis J; 2001 Sep; 20(9):874-9. PubMed ID: 11734767
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study.
Flaherman V; Li S; Ragins A; Masaquel A; Kipnis P; Escobar GJ
Clin Ther; 2010 Dec; 32(13):2220-9. PubMed ID: 21316538
[TBL] [Abstract][Full Text] [Related]
15. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
Figueras-Aloy J; Carbonell-Estrany X; Quero J;
Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
[TBL] [Abstract][Full Text] [Related]
16. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
[TBL] [Abstract][Full Text] [Related]
17. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
18. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
[TBL] [Abstract][Full Text] [Related]
19. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
20. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
Winterstein AG; Knox CA; Kubilis P; Hampp C
JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
